Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jade Biosciences, Inc. - Common Stock (NQ:JBIO)

19.24 -0.46 (-2.34%)
Streaming Delayed Price Updated: 3:51 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 303,774
Open 20.01
Bid (Size) 19.23 (200)
Ask (Size) 19.26 (100)
Prev. Close 19.70
Today's Range 18.75 - 20.15
52wk Range 6.670 - 28.00
Shares Outstanding 28,985,019
Dividend Yield 12.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Jade Biosciences
Via GlobeNewswire

Performance

YTD
+35.9%
+35.9%
1 Month
-13.0%
-13.0%
3 Month
-27.3%
-27.3%
6 Month
+19.9%
+19.9%
1 Year
+148.3%
+148.3%

More News

Read More
News headline image
Jade Biosciences Announces Pricing of Public Offering of Common Stock
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces Proposed Underwritten Public Offering
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials ↗
Via MarketBeat
News headline image
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces $45 Million Private Placement
From Jade Biosciences
Via GlobeNewswire
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
News headline image
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
From Jade Biosciences
Via GlobeNewswire

Frequently Asked Questions

Is Jade Biosciences, Inc. - Common Stock publicly traded?
Yes, Jade Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Jade Biosciences, Inc. - Common Stock trade on?
Jade Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jade Biosciences, Inc. - Common Stock?
The ticker symbol for Jade Biosciences, Inc. - Common Stock is JBIO on the Nasdaq Stock Market
What is the current price of Jade Biosciences, Inc. - Common Stock?
The current price of Jade Biosciences, Inc. - Common Stock is 19.24
When was Jade Biosciences, Inc. - Common Stock last traded?
The last trade of Jade Biosciences, Inc. - Common Stock was at 07/29/26 03:51 PM ET
What is the market capitalization of Jade Biosciences, Inc. - Common Stock?
The market capitalization of Jade Biosciences, Inc. - Common Stock is 557.67M
How many shares of Jade Biosciences, Inc. - Common Stock are outstanding?
Jade Biosciences, Inc. - Common Stock has 558M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.